If you are exploring weight loss injections in the UK, two names are likely to appear at the top of every search result: Mounjaro and Wegovy. Both are once-weekly injectable treatments with strong clinical evidence behind them – yet they work through different mechanisms, suit different patients, and have distinct track records in clinical trials.

This guide provides a balanced, evidence-based comparison of Mounjaro (tirzepatide) and Wegovy (semaglutide 2.4 mg) to help you understand your options. The right choice will always depend on your individual health profile, and should be made in close partnership with a qualified prescriber.

What Are Mounjaro and Wegovy?

Mounjaro (tirzepatide)

Mounjaro is the brand name for tirzepatide, developed by Eli Lilly. It is the first approved dual GIP/GLP-1 receptor agonist – meaning it activates two incretin hormone pathways simultaneously: glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). This dual mechanism produces a stronger effect on appetite suppression, metabolic regulation, and fat loss than single-receptor GLP-1 treatments.

In the UK, tirzepatide is licensed both for the management of type 2 diabetes and for chronic weight management in adults with obesity or overweight accompanied by at least one weight-related comorbidity, in line with NICE TA1026 (2024).

Wegovy (semaglutide 2.4 mg)

Wegovy is the brand name for semaglutide at a dose of 2.4 mg, manufactured by Novo Nordisk. It is a GLP-1 receptor agonist – the same drug class as Ozempic, but at a higher dose formulated specifically for chronic weight management. Semaglutide mimics the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve insulin secretion.

Wegovy received MHRA approval for weight management in the UK in 2023 and is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related health condition, in line with NICE TA875 (2023).

How Do They Work?

Mounjaro’s dual-action mechanism targets both GIP and GLP-1 receptors in the brain and gut. GIP receptor activation amplifies the insulin response and promotes fat utilisation, while GLP-1 receptor activation reduces appetite and slows digestion. The combined effect is thought to be synergistic, producing greater reductions in body weight than either pathway alone.

Wegovy activates GLP-1 receptors in the hypothalamus and gastrointestinal tract, reducing appetite signals, slowing the rate at which the stomach empties, and improving the body’s insulin response following meals. GLP-1 receptor agonism has a well-established, decade-long evidence base in both diabetes and obesity management.

Clinical Evidence: What Do the Trials Show?

It is important to note that SURMOUNT-1 and STEP-1 were independent trials with different study populations and durations – they were not head-to-head comparisons. Direct comparisons between the two medications should be interpreted with caution.

For cardiovascular outcomes, the SELECT trial (2023) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease – a landmark result for the GLP-1 class. Cardiovascular outcome data for tirzepatide continues to accumulate through the SURMOUNT-MMO trial.

Mounjaro vs Wegovy: Side-by-Side Comparison

Side Effects: What to Expect

Both Mounjaro and Wegovy share a broadly similar side effect profile, primarily affecting the gastrointestinal system. Side effects are typically most pronounced when beginning treatment or after a dose increase, and tend to diminish over time as the body adapts.

Common side effects (both medications)

• Nausea – the most frequently reported side effect; generally mild to moderate and transient
• Vomiting
• Diarrhoea or constipation
• Abdominal pain or bloating
• Reduced appetite – an intended therapeutic effect, but may affect nutritional intake
• Fatigue, particularly during the initial weeks of treatment
• Injection site reactions: redness, bruising, or mild discomfort

Less common but clinically significant side effects

Seek prompt medical attention if you experience any of the following:

• Pancreatitis: severe, persistent upper abdominal pain, often radiating to the back. Discontinue treatment and seek urgent medical review.
• Thyroid changes: both drug classes carry a theoretical risk based on preclinical (animal) data. Report any new neck lump, hoarseness, or difficulty swallowing to your clinician.
• Gallbladder disease: rapid weight loss is a known risk factor for gallstone formation. Report persistent upper right abdominal pain.
• Hypoglycaemia: low blood glucose is more likely when these medications are taken alongside insulin or sulphonylureas. Monitor blood glucose as directed.
• Acute kidney injury: secondary to severe dehydration from vomiting or diarrhoea. Maintain adequate fluid intake and seek medical advice if dehydration is severe.

NHS Eligibility and Access in the UK

NHS access to both Mounjaro and Wegovy currently remains limited, with provision primarily through specialist weight management services. Eligibility criteria are defined by NICE guidance.

NICE eligibility: tirzepatide (Mounjaro) – TA1026 (2024)

• BMI of 35 kg/m² or above
• OR BMI of 30-34.9 kg/m² with at least one weight-related comorbidity (e.g. type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or cardiovascular disease)
• Adult patients aged 18 and over
• Must be prescribed within a specialist weight management service
• Current NICE guidance recommends treatment for up to 2 years; continuation is subject to clinical review

NICE eligibility: semaglutide 2.4 mg (Wegovy) – TA875 (2023)

• BMI of 35 kg/m² or above with at least one weight-related comorbidity
• Must be prescribed alongside a reduced-calorie diet and increased physical activity programme
• As part of a specialist weight management service
• Treatment limited to 2 years under current NICE guidance

Both medications are also available via private prescription through regulated online and in-person clinics and pharmacies – subject to a comprehensive clinical consultation. At Pharmazon Express, all prescriptions are issued exclusively by registered independent prescribers following a thorough medical assessment.

Who Is Each Medication Best Suited For?

Mounjaro may be preferable if you:

• Have not achieved adequate weight loss with a GLP-1 medication previously
• Have type 2 diabetes alongside obesity – tirzepatide addresses both simultaneously
• Are seeking the highest-magnitude weight loss currently available in licensed therapy
• Are enrolled in or eligible for a specialist weight management programme
• Are able to commit to a 20-week dose escalation schedule

Wegovy may be preferable if you:

• Have previously used semaglutide (e.g. Ozempic) and tolerated it well
• Have overweight (BMI ≥27) rather than obesity, with a weight-related comorbidity
• Have established cardiovascular disease and would benefit from the SELECT trial outcomes data
• Are on a specialist pathway where semaglutide is currently the preferred treatment
• Prefer a medication with a longer UK-market history

Dosing and Administration

Both medications are self-administered as a subcutaneous injection (under the skin of the abdomen, thigh, or upper arm) once per week, on the same day each week. Both come as pre-filled, multi-dose injection pens.

Mounjaro – dose escalation schedule

• Weeks 1-4: 2.5 mg once weekly
• Weeks 5-8: 5.0 mg once weekly
• Weeks 9-12: 7.5 mg once weekly
• Weeks 13-16: 10.0 mg once weekly
• Weeks 17-20: 12.5 mg once weekly
• Week 21 onwards: 15.0 mg once weekly (maximum maintenance dose)

Wegovy – dose escalation schedule

• Weeks 1-4: 0.25 mg once weekly
• Weeks 5-8: 0.50 mg once weekly
• Weeks 9-12: 1.0 mg once weekly
• Weeks 13-16: 1.7 mg once weekly
• Week 17 onwards: 2.4 mg once weekly (maintenance dose)

Gradual dose escalation is essential to minimise gastrointestinal side effects. Your prescribing clinician may advise pausing or slowing escalation if side effects are difficult to manage.

Lifestyle: The Essential Foundation

Both medications are most effective – and are clinically indicated – as part of a comprehensive lifestyle modification programme. NICE guidance and the NHS Long Term Plan emphasise that pharmacotherapy for obesity should always be delivered alongside:

• A nutritionally balanced, calorie-reduced diet – typically a 500-600 kcal daily deficit from estimated total energy expenditure
• Regular physical activity – at least 150 minutes of moderate-intensity aerobic exercise per week, as recommended by UK Chief Medical Officers
• Behavioural and psychological support where available – including CBT-based weight management programmes
• Regular clinical monitoring – weight, BMI, blood pressure, blood glucose (particularly in patients with type 2 diabetes or prediabetes)

Evidence consistently shows that patients who discontinue GLP-1 or GIP/GLP-1 treatments without sustaining lifestyle modifications regain a significant proportion of lost weight. Continued clinical support and follow-up are therefore strongly recommended throughout and beyond the treatment period.

Frequently Asked Questions

Can I switch from Wegovy to Mounjaro (or vice versa)?

It may be possible to transition between these treatments, but any switch must be supervised by a prescribing clinician. A full reassessment of your clinical response, side effect history, BMI, and overall health will be required. Do not attempt to switch medications without medical guidance.

Is Mounjaro more effective than Wegovy?

Clinical trial data suggests that tirzepatide (Mounjaro) produces greater average weight loss at its highest studied doses than semaglutide 2.4 mg (Wegovy). However, these were separate trials – not head-to-head studies – and individual responses vary considerably. Effectiveness is not the sole determinant of suitability; your prescriber will consider your full clinical picture.

How long will I need to stay on treatment?

Current NICE guidance recommends treatment for up to 2 years on NHS pathways, with continuation subject to clinical review. Evidence indicates that weight regain typically occurs when treatment is stopped, particularly in the absence of sustained lifestyle changes. Long-term treatment decisions should be made collaboratively with your healthcare team.

Can I access these treatments privately?

Yes. Both Mounjaro and Wegovy can be prescribed via regulated private clinics and pharmacies, including online services, following an appropriate clinical consultation. Pharmazon Express offers online consultations with registered independent prescribers for patients who meet clinical eligibility criteria.